Equities Analysts Set Expectations for CAPR FY2025 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Capricor Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will earn ($1.39) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $30.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Several other research firms have also recently issued reports on CAPR. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler assumed coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $14.06 on Wednesday. The firm’s 50 day moving average price is $15.34 and its 200-day moving average price is $11.66. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a market cap of $639.31 million, a PE ratio of -13.26 and a beta of 4.08.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at about $133,000. Rhumbline Advisers purchased a new stake in Capricor Therapeutics during the second quarter valued at approximately $147,000. The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics in the third quarter worth approximately $161,000. Sassicaia Capital Advisers LLC bought a new position in Capricor Therapeutics in the third quarter worth approximately $192,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 15,872 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.